Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner Sells 29,314 Shares

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher J. Senner sold 29,314 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now owns 779,607 shares of the company’s stock, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Exelixis Stock Up 1.7 %

EXEL stock opened at $37.53 on Thursday. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $37.64. The firm has a market cap of $10.50 billion, a PE ratio of 21.20, a P/E/G ratio of 1.13 and a beta of 0.53. The business has a 50 day moving average of $34.34 and a 200-day moving average of $31.50.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EXEL. Invesco Ltd. lifted its holdings in Exelixis by 308.1% during the fourth quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Norges Bank bought a new stake in shares of Exelixis in the fourth quarter valued at approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock valued at $82,730,000 after buying an additional 1,907,167 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Exelixis by 104.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after acquiring an additional 1,613,482 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after purchasing an additional 991,494 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of research reports. UBS Group boosted their target price on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Barclays boosted their price target on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. Citigroup lifted their price target on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 target price on shares of Exelixis in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.